From the Journals
To engage injection drug users in HCV care, go to where they are
While HCV screening and diagnosis rates varied across states, postpartum follow-up rates were universally low.
A variety of combo drug treatments proved effective in treating HCV genotype 3 to achieve sustained virologic response.
Large study of pregnant women highlights the potential value of universal screening for hepatitis C virus.
An estimated one in three inmates in the United States has chronic HCV.
The levonorgestrel and ethinyl estradiol contraceptive is contraindicated in obese women.
Adults with a history of hepatocellular carcinoma had a significantly reduced risk of death after treatment of HCV infections with DAAs.
In sharp contrast with the viral hepatitis findings, mortality rates among patients with ALD and NAFLD have increased.
The SS/LS ratio is significantly higher in patients with HCV than in those with alcohol-related liver disease (ALD).
No prior authorization will be necessary for a specific combination of direct-acting antiviral agents starting July 15.
Diabetes incidence was lower in hepatitis C patients treated with DAAs than in untreated patients.